

PB 36 of 2020

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 3)

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.

Dated 29th April 2020

Thea Daniel

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1 Name

2 Commencement 1

3 Authority 1

4 Schedule 1

Schedule 1—Amendments 2

National Health (Continued Dispensing - Emergency Measures) Determination 2020 2

1 Name

1. This instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.3)*.
2. This instrument may also be cited as PB 36 of 2020.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 May 2020.* |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

**3 Authority**

 This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

1. Schedule 1, after entry for Brexpiprazole in the form Tablet 4 mg

*insert:*

|  |  |  |
| --- | --- | --- |
| Brigatinib | Pack containing 7 tablets 90 mg and 21 tablets 180 mg | Oral |
|  | Tablet 30 mg | Oral |
|  | Tablet 90 mg | Oral |
|  | Tablet 180 mg | Oral |

1. Schedule 1, entry for Folinic acid

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Injection containing calcium folinate equivalent to 1000 mg folinic acid in 100 mL | Injection |

1. Schedule 1, entry for Nystatin

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Cream 100,000 units per g, 15 g | Application |

1. Schedule 1, entry for Sapropterin

*insert as first entry:*

|  |  |  |
| --- | --- | --- |
|  | Powder for oral solution 500 mg (as dihydrochloride) | Oral |

1. Schedule 1, after entry for Umeclidinium with vilanterol

*insert:*

|  |  |  |
| --- | --- | --- |
| Upadacitinib | Tablet 15 mg | Oral |